The following articles (labelled with PubMed ID or TBD) are for your review
||Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
||Icahn School of Medicine at Mount Sinai
||Discovery, Development, and SAR of Aminothiazoles as LIMK Inhibitors with Cellular Anti-Invasive Properties.
||Cancer Research Technology
||Design, synthesis and biological characterization of selective LIMK inhibitors.
||Amakem Therapeutics N.V.
||Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
||Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.
||Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
||Roche Palo Alto
||Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
||Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
||Bristol-Myers Squibb Research and Development
||A quantitative analysis of kinase inhibitor selectivity.
||Comprehensive analysis of kinase inhibitor selectivity.
||Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38a MAP kinase inhibitors.
||Bristol-Myers Squibb Pharmaceutical Research Institute
||AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
||Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
||Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.